

# BlackRock Global Bond

Quarterly Investment Option Update

31 March 2020

#### **Aim and Strategy**

To generate capital and income return for investors seeking exposure to international fixed income markets, including Australia. The option aims to outperform the Bloomberg Barclays Global Aggregate Index (Australian dollar hedged) over rolling three-year periods. The option invests predominantly in international debt securities and foreign currency exposures. These include a broad universe of investment instruments, including fixed interest securities, mortgage securities, assetbacked securities, derivatives, repurchase agreements, stock lending and units in pooled investment funds.

## **Investment Option Performance**

To view the latest investment performances for each product please visit <a href="mailto:amp.com.au">amp.com.au</a>

## **Investment Option Overview**

Investment Category	Global Fixed Interest
Suggested Investment timeframe	2 years
Relative risk rating	4 / Medium
Investment style	Core
Manager style	Single Manager

Sector Allocation	%
Government	39.64
Corporate	29.25
Securitised	28.75
Other	2.36
Regional Allocation	%
UK	1.20
Europe (ex UK)	26.11
North America	50.96
Japan	2.12
Asia (ex Japan)	9.01
Other	10.6
Quality Allocation	%
AAA	34.70
AA	12.91
A	21.32
BBB	21.11
BB>	3.52
Not Rated/Cash	6.44

Asset Allocation	Benchmark (%)	Actual (%)	
International Fixed Interest and Cash	100	100	

#### **Portfolio Summary**

The strategy underperformed its benchmark over the quarter. In a period of heightened volatility and risk aversion, the investment option's overweight exposure to riskier assets in areas of credit and emerging markets was the main source of under-performance. Within credit strategies, the main detractors included an overweight exposure to securitized assets, investment grade industrials and select high yield names. In addition, an overweight to investment grade utilities and senior financials also had a negative impact on performance. This was partially offset by a credit protection strategy implemented through a broad CDX Index hedge.

Macro rates strategies detracted overall. The main detractors included yield curve positioning and off-benchmark allocation to inflation-linked bonds, both in the US. The strategy's underweight exposures to Germany duration and UK government bonds also detracted, as did its overweight to Greece and Spain government bonds. This was partially offset by the overall US, Japan and Canada duration overweight positions, and an underweight in French government bonds. Developed market currency positions posted negative returns overall over the quarter. The strategy's long Japanese yen against the US dollar position detracted in aggregate, while an overall short euro bias added to returns.

#### **Investment Option Commentary**

Going into the unprecedented volatility, the strategy favoured a high-quality and highly diversified portfolio which helped mitigate the tail-risk to an extent. The strategy has been maintaining its positioning being mindful of the liquidity constraints in markets and it continues to hold its high-conviction strategies in the strategy. The strategy maintains it overweight allocations to spread assets where recent weakness appears driven by market dislocations and not fundamentals. Elsewhere, the strategy has increased its overweight allocations in higher quality areas which have sold off indiscriminately, primarily through securitized assets.

#### **Outlook**

The strategy's base case positioning is for the disruption to persist into the end of the second quarter, with a rebound in the second half of the year supported by ongoing meaningful policy easing. The clear risk to this case is a more protracted impact from the Virus which lasts through to the end of 2020 and a rebound in economic activity which does not come through until 2021.

Governments are reacting aggressively, ramping up their fiscal spending plans across the globe. U.S. President Donald Trump, for example, has now signed the largest fiscal package in US history, worth more than \$2tn including an injection of loans, tax breaks and direct payments. It is evident that global central banks are willing to provide ample liquidity to the system for as long as the uncertainty and business disruption persists. There is a clear willingness from central banks to do whatever it takes to help combat the economic fallout.

The strategy is most constructive in areas which have first, seen indiscriminate selling resulting in valuations dislocating from fundamentals meaningfully and second, where major central banks – most notably the Fed and the ECB - are purchasing assets most aggressively. Given the sheer scale of these asset purchases, this technical support is a major tailwind. Assets likely to benefit includes higher-quality areas of credit markets in the US and peripheral names in sovereign markets in the Eurozone.

Markets will ultimately settle down if three conditions are met: 1) visibility on the ultimate scale of the coronavirus outbreak and evidence the infection rate as peaked over the long term; 2) deployment of credible and coordinated policy packages; and 3) confidence that financial markets are functioning properly. Once there is more clarity on the scale and impact of the outbreak, the policy response that has been seen is setting the stage for an eventual – and strong – recovery.

### **Availability**

Product name	APIR
AMP Flexible Lifetime Super	AMP1102AU
AMP Flexible Super - Retirement account	AMP1338AU
AMP Flexible Super - Super account	AMP1467AU
CustomSuper	AMP1102AU
Flexible Lifetime - Allocated Pension	AMP1107AU
Flexible Lifetime - Term Pension	AMP1111AU
Flexible Lifetime Investment	AMP1116AU
Flexible Lifetime Investment (Series 2)	AMP1403AU
SignatureSuper	AMP1113AU
SignatureSuper Allocated Pension	AMP1142AU

#### **Contact Details**

Web: www.amp.com.au Email: askamp@amp.com.au

Phone: 131 267



#### What you need to know

This publication has been prepared by AMP Life Limited ABN 84 079 300 379, AFSL No. 233671 (AMP Life). The information contained in this publication has been derived from sources believe to accurate and reliable as at the date of this document. Information provided in this investment option update are views of the underlying Investment Manager only and not necessarily the views of the AMP Group. No representation is given in relation to the accuracy or completeness of any statement contained in it. Whilst care has been taken in the preparation of this publication, to the extent permitted by law, no liability is accepted for any loss or damage as a result of reliance on this information. AMP Life is part of the AMP Group. In providing the general advice, AMP Life and AMP Group receives fees and charges and their employees and directors receive salaries, bonuses and other benefits.

The information in this document is of a general nature only and does not take into account your financial situation, objectives and needs. Before you make any investment decision based on the information contained in this document you should consider how it applies to your personal objectives, financial situation and needs, or speak to a financial planner.

The investment option referred to in this publication is available through products issued by AMP Superannuation Limited ABN 31 008 414 104, AFSL No. 233060 (ASL) and/or AMP Life. Before deciding to invest or make a decision about the investment options, you should read the current Product Disclosure Statement for the relevant product, available from ASL, AMP Life or your financial planner.

Any references to the "Fund", strategies, asset allocations or exposures are references to the underlying managed fund that the investment option either directly or indirectly invests in (underlying fund). The investment option's aim and strategy mirrors the objective and investment approach of the underlying fund. An investment in the investment option is not a direct investment in the underlying fund.

Neither AMP Life, ASL, any other company in the AMP Group nor underlying fund manager guarantees the repayment of capital or the performance of any product or particular rate of return referred to in this document. Past performance is not a reliable indicator of future performance.